Strategies for neuroprotection

Abstract

While glaucoma may be a better candidate for the implementation of neuroprotective strategies than more acute CNS diseases, the failure of clinical neuroprotective trials in stroke should prompt both clinical and basic researchers studying glaucoma to develop better methods to test these agents in animal models, as well as improve methods to quantify glaucomatous damage in clinical studies. The inadequacy of visual fields to quantify glaucomatous progression may hamper current and future clinical trials evaluating neuroprotective agents, and thus may fail to identify potentially beneficial agents and delay the implementation of these strategies.